◼ Archived
Health
Nearly 1 in 6 Kids on GLP-1s Developed This Problem Within a Year
New research indicates nearly 17% of children using GLP-1 receptor agonists developed nutritional deficiencies within one year of treatment.
Pediatric Obesity
4 trends tracked about this subject — the full history, oldest to newest below.
◼ Archived
Business
🔮 fades ✓
Novo’s blockbuster hopes for CKD program dwindle after more phase 3 trials scrapped
Novo Nordisk faces a divergent clinical outlook as its pediatric obesity trials succeed while heart drug programs for CKD suffer setbacks.
◼ Archived
Business
🔮 fades ✗
Novo Nordisk Says Wegovy Shot Helped Children Lose Weight in Trial
Novo Nordisk's Wegovy shows weight-loss results in young children during trial data releases.
◼ Archived
Business
🔮 fades ✗
Novo scraps two more heart drug trials, further dimming growth beyond obesity
Novo Nordisk faces a diverging trajectory as it meets pediatric obesity goals but terminates two heart disease drug trials.